Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis

Neurology

Volumn 80, Issue 3, 2013, Pages 234-241

  Giorgio, Antonio ^a   Battaglini, Marco ^a   Rocca, Maria Assunta ^b   De Leucio, Alessandro ^a   Absinta, Martina ^b   Van Schijndel, Ronald ^c   Rovira, Alex ^d   Tintoré, Mar ^d   Chard, Declan ^e   Ciccarelli, Olga ^e   Enzinger, Christian ^f   Gasperini, Claudio ^g   Frederiksen, Jette ^h   Filippi, Massimo ^b   Barkhof, Frederik ^c   De Stefano, Nicola ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN DAMAGE; BRAIN REGION; BRAIN STEM; CEREBELLUM; CINGULATE GYRUS; CORONA RADIATA (BRAIN); CORPUS CALLOSUM; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEMISPHERE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE; OPTIC NEURITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPINAL CORD; WHITE MATTER LESION;

ADULT; AGE OF ONSET; ALGORITHMS; BRAIN; CLUSTER ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES;

EID: 84873681297     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31827debeb     Document Type: Article

References (38)

1. Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol 2012;11:157-169.
2. Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008;65:727-732.
3. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-817. (Pubitemid 351294716)
4. Tintoré M, Rovira A, Rio J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006;67:968-972. (Pubitemid 44454586)
5. Ruet A, Deloire MS, Ouallet JC, et al. Predictive factors for multiple sclerosis in patients with clinically isolated spinal cord syndrome. Mult Scler 2011;17:312-318.
6. Minneboo A, Barkhof F, Polman CH, et al. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol 2004;61:217-221. (Pubitemid 38197554)
7. Narayanan S, Fu L, Pioro E, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997;41: 385-391. (Pubitemid 27114050)
8. Dalton C, Bodini B, Samson R, et al. Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2012;18:322-328.
9. Kincses ZT, Ropele S, Jenkinson M, et al. Lesion probability mapping to explain clinical deficits and cognitive performance in multiple sclerosis. Mult Scler 2011;17: 681-689.
10. Di Perri C, Battaglini M, Stromillo ML, et al. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis. Arch Neurol 2008;65:236-243. (Pubitemid 351240787)
11. Bodini B, Battaglini M, De Stefano N, et al. T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2011;82:72-77.
12. Vellinga MM, Geurts JJ, Rostrup E, et al. Clinical correlations of brain lesion distribution in multiple sclerosis. J Magn Reson Imaging 2009;29:768-773.
13. Sombekke MH, Vellinga MM, Uitdehaag BM, et al. Genetic correlations of brain lesion distribution in multiple sclerosis: an exploratory study. AJNR Am J Neuro-radiol 2011;32:695-703.
14. Charil A, Zijdenbos AP, Taylor J, et al. Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis: application to 452 patient data sets. Neuroimage 2003;19:532-544. (Pubitemid 36918200)
15. Ceccarelli A, Rocca MA, Pagani E, et al. The topographical distribution of tissue injury in benign MS: a 3T multi-parametric MRI study. Neuroimage 2008;39:1499-1509.
16. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996;39:6-16. (Pubitemid 26052212)
17. Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry 1962;25:315-320.
18. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996;6:259-274. (Pubitemid 26246382)
19. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-1249. (Pubitemid 44563835)
20. Comi G, Filippi M, Barkhof F, et al. Effect of early inter-feron treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582. (Pubitemid 32488815)
21. Comi G, Martinelli V, Rodegher M, et al. Effect of glatir-amer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-1511.
22. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(suppl 1): S208-S219. (Pubitemid 39421720)
23. Andersson JLR, Jenkinson M, Smith S. Non-linear optimisation. FMRIB technical report TR07JA1. Available at: www. fmrib.ox.ac.uk/analysis/techrep. 2007. Accessed November 27, 2012.
24. Andersson JLR, Jenkinson M, Smith S. Non-linear registration, aka Spatial normalisation. FMRIB technical report TR07JA2. Available at: www.fmrib.ox.ac.uk/analysis/te-chrep. 2007. Accessed November 27, 2012.
25. Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp 2002;15:1-25. (Pubitemid 34020610)
26. Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuro-image 2009;44:83-98.
27. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120(pt 11):2059-2069. (Pubitemid 27493740)
28. Jafari N, Kreft KL, Flach HZ, et al. Callosal lesion predicts future attacks after clinically isolated syndrome. Neurology 2009;73:1837-1841.
29. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
30. Montalban X, Tintoré M, Swanton J, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010;74:427-434.
31. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular inter-feron beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
32. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-397. (Pubitemid 47189673)
33. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-997.
34. Reuter F, Zaaraoui W, Crespy L, et al. Cognitive impairment at the onset of multiple sclerosis: relationship to lesion location. Mult Scler 2011;17:755-758.
35. Calabrese M, Battaglini M, Giorgio A, et al. Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis. Neurology 2010;75: 1234-1240.
36. Sepulcre J, Masdeu JC, Pastor MA, et al. Brain pathways of verbal working memory: a lesion-function correlation study. Neuroimage 2009;47:773-778.
37. Sepulcre J, Masdeu JC, Sastre-Garriga J, et al. Mapping the brain pathways of declarative verbal memory: evidence from white matter lesions in the living human brain. Neu-roimage 2008;42:1237-1243.
38. Lee MA, Smith S, Palace J, et al. Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? Brain 1999;122(pt 7):1261-1270. (Pubitemid 29324847)